Pharmaceutical Executive reporter discusses how a coalition of data, computational power, and AI is bringing the full potential of in silico medicine out of the realm of science fiction. Read the full story here.
This is the first AI-based virtual patient for multiple myeloma, said Colin Hill, the Cambridge, Mass.-based company’s co-founder and chief executive. It is traditionally difficult to predict how specific drugs or combinations of drugs might help individual multiple...
Peggy Maguire, president of Cambia Health Foundation, shares how Cambia worked with GNS to use predictive analytics and identify members of Cambia’s Medicare Advantage population that could benefit from an extra layer of support. Read the full article...
“The company Hill runs, GNS Healthcare, found a genetic signature in some multiple myeloma patients that suggested they would benefit from a transplant. For others, the risky, painful, and expensive procedure would probably only provide false hope.” Read...
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.